AHA 2005

Warfarin Trumps Platelet Agents in Atrial Fibrilation

For atrial fibrillation, oral anti-coagulation remains the treatment of choice despite the potential of an anti-platelet regimen based on aspirin and clopidogrel, according to the ACTIVE-W trial. Stuart Connolly from McMaster University presented the findings.

Click here for all the interviews from AHA 2005

Similar Interviews

  • Audio Journal of Cardiovascular Medicine: Rapid Genotype Assay for Individualized Warfarin Dosing">Audio Journal of Cardiovascular Medicine: Rapid Genotype Assay for Individualized Warfarin Dosing
  • Jeffrey Anderson Douglas Zipes JEFFREY ANDERSON, University of Utah, Salt Lake City COMMENT: DOUGLAS ZIPES, University of Indiana, Indianapolis REFERENCE: Abstract 1020-89, American College

  • Audio Journal of Cardiovascular Medicine: May 2006 - In the company of James Tcheng">Audio Journal of Cardiovascular Medicine: May 2006 - In the company of James Tcheng
  • Annual Meeting of the American College of Cardiology March 11-14, 2006, Atlanta: Atheroma Reversal, Statins for Acute Coronary Syndromes, Targeting

  • Catheter Ablation: Better than Multi Drug Therapy for Paroxysmal Atrial Fibrillation
  • Carlo Pappone, San Raffaele University Hospital, Milan American College of Cardiology Annual Scientific Session March 11-14, 2006, Atlanta The use of circumferential

    Post a comment

    Subscribe to Audio Medica Podcast